# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0229 |
| Population Package | PP-0229 |
| Title | Gastric Cancer Survivorship |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |
| Last Updated | 2026-08-09 |

---

# QA Basis

This QA review evaluates PP-0229 against:

1. The approved and locked PP-0229 Decision Batch.
2. CORE_WORKING_RULES v1.7.
3. FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1.
4. The approved Gold Discussion depth/format reference.
5. The completed Gold artifact references supplied in the project Source Files.
6. The PP Registry and adjacent-package ownership.
7. The supplied gastric-cancer clinical Source Materials.

The package is treated as a governed knowledge product, not as a free-form summary.

---

# Layer 1 — Content QA

| Criterion | Result | QA Note |
|---|---|---|
| Single educational question | PASS | Package answers what survivorship care means and what long-term needs may remain after gastric cancer treatment. |
| Scope respected | PASS | Survivorship is the central topic; surveillance, recurrence detection, long-term follow-up operations, and detailed toxicity are delegated. |
| Complete coverage | PASS | Survivorship planning, long-term sequelae, post-gastrectomy nutrition, function, quality of life, prevention, psychosocial care and coordination are covered. |
| Internal consistency | PASS | CKO, KP, Evidence Package and QA use the same scope and terminology. |
| Logical organization | PASS | Content progresses from survivorship concept to care planning, sequelae, health promotion, coordination, boundaries and patient questions. |
| Knowledge blocks complete | PASS | Independent patient-facing blocks cover the major survivorship domains. |
| Common misconceptions addressed | PASS | Dedicated misconception section included. |
| Patient questions included | PASS | Practical questions are provided without prescribing individualized care. |
| Knowledge Graph complete | PASS | Prerequisite, related and downstream relationships are defined. |
| Adjacent PP overlap controlled | PASS | Explicit boundaries separate PP-0220, PP-0221, PP-0228, PP-0230 and PP-0231. |
| Patient-facing scope appropriate | PASS | The package explains survivorship without turning into individualized management. |
| Long-term nutrition represented | PASS | Gastric-cancer-specific nutritional consequences are a major knowledge block. |
| Quality of life represented | PASS | Physical, GI, functional and psychosocial dimensions are included. |

---

# Layer 2 — Clinical QA

| Criterion | Result | QA Note |
|---|---|---|
| Scientifically accurate within source-supported scope | PASS | Major clinical claims are anchored to supplied NCCN and supporting project sources. |
| Consistent with NCCN Gastric Cancer v2.2026 | PASS | Survivorship principles, long-term sequelae, post-gastrectomy nutrition, health behaviors and care coordination are represented conservatively. |
| Consistent with ESMO-ASCO 2023 | PASS | Broad survivorship, psychosocial, rehabilitation, prevention and health-promotion concepts are represented without overextension. |
| Long-term sequelae accurately framed | PASS | Weight loss, diarrhea, neuropathy, fatigue and bone health are described as survivorship issues. |
| Post-gastrectomy consequences accurately framed | PASS | Nutritional deficiencies, dumping syndrome, postprandial fullness and bacterial overgrowth are represented as long-term concerns. |
| Nutritional deficiency language appropriate | PASS | B12, D, calcium, iron and zinc are described as monitoring/management considerations, not universal prescriptions. |
| Bone-health language appropriate | PASS | Bone density and vitamin D are described in guideline-supported terms. |
| Healthy behavior language appropriate | PASS | No guarantee of recurrence prevention is claimed. |
| Primary-care role accurately represented | PASS | Defined roles and coordination are presented as survivorship principles. |
| Survivorship versus surveillance correctly distinguished | PASS | Surveillance is treated as a component, while PP-0220 retains detailed ownership. |
| Recurrence detection boundary respected | PASS | No duplicate recurrence-detection algorithm is included. |
| Long-term follow-up boundary respected | PASS | Operational follow-up is delegated to PP-0230. |
| Toxicity boundary respected | PASS | Acute/detailed treatment toxicity is delegated to PP-0231. |
| No unsupported clinical claim | PASS | Claims are conservative and source-traceable. |
| No unsafe medical advice | PASS | No individualized treatment, dosing, supplement prescription, or surveillance schedule is provided. |
| No false cure implication | PASS | Survivorship is explicitly separated from cancer status. |
| No overclaim about lifestyle | PASS | Healthy behaviors are not presented as guarantees against recurrence. |

---

# Layer 3 — Educational QA

| Criterion | Result | QA Note |
|---|---|---|
| Plain language | PASS | Medical terminology is explained in patient-facing language. |
| Patient-friendly wording | PASS | Questions and practical explanations are used throughout. |
| Learning objectives satisfied | PASS | Objectives map to the clinical knowledge blocks. |
| Logical learning progression | PASS | Framework → long-term effects → health promotion → coordination → patient questions. |
| Common misconceptions addressed | PASS | Ten major misconceptions are explicitly corrected. |
| Practical usefulness | PASS | Survivorship-care questions are provided for clinical discussion. |
| Appropriate uncertainty communication | PASS | Context-dependent decisions are explicitly identified. |
| Avoids overpromising | PASS | No guarantee of cure, recurrence prevention, or universal survivorship outcome. |
| Encourages clinician discussion | PASS | Individualized management is consistently redirected to the care team. |
| Appropriate educational boundary | PASS | Package does not attempt to diagnose recurrence or prescribe personalized care. |
| Patient journey fit | PASS | Package is positioned after treatment and across long-term survivorship. |
| Accessibility | PASS | Content is organized into short, concept-specific blocks. |

---

# Layer 4 — Governance QA

| Criterion | Result | QA Note |
|---|---|---|
| CKO completed | PASS | 01_CKO.md produced. |
| Knowledge Passport completed | PASS | 02_KNOWLEDGE_PASSPORT.md produced. |
| Evidence Package completed | PASS | 03_PRIMARY_EVIDENCE_PACKAGE.md produced. |
| QA Report completed | PASS | This artifact completed. |
| Gold specification followed | PASS | Four-artifact structure preserved. |
| Approved Decision Batch respected | PASS | Locked PP-0229 scope implemented without reopening decisions. |
| Source-first rule respected | PASS | PP-specific clinical sources and governance sources were searched first. |
| Gold reference depth preserved | PASS | Artifacts are full-depth and not compacted into an executive summary. |
| Absolute Gold-depth rule | PASS | Gold reference is treated as minimum depth. |
| Artifact naming compliant | PASS | Standard four artifact names used. |
| Versioning compliant | PASS | Semantic version 1.0.0 used. |
| Knowledge Graph complete | PASS | Prerequisite, related and downstream links included. |
| Boundary ownership preserved | PASS | Core / Supporting / Explicitly Excluded / Delegated-to PP structure used. |
| User-controlled PP sequence respected | PASS | PP-0229 was explicitly requested by the Project Coordinator. |
| No unsolicited next PP execution | PASS | Production stops after PP-0229. |
| Repository-ready structure | PASS | Four Markdown artifacts packaged in one PP directory and ZIP. |

---

# Layer 5 — Evidence Traceability QA

## Major Claim Domains

| Claim Domain | Traceability | Result |
|---|---|---|
| Survivorship framework | NCCN v2.2026; ESMO-ASCO 2023 | PASS |
| Long-term gastric-cancer sequelae | NCCN v2.2026 | PASS |
| Post-gastrectomy nutrition | NCCN v2.2026 | PASS |
| Bone health | NCCN v2.2026 | PASS |
| Healthy behaviors | NCCN; ESMO-ASCO | PASS |
| PCP coordination | NCCN v2.2026 | PASS |
| Preventive screening | NCCN; ESMO-ASCO | PASS |
| Psychosocial survivorship | ESMO-ASCO; ACS | PASS |
| Surveillance boundary | NCCN + PP Registry | PASS |
| Recurrence-detection boundary | PP Registry + approved architecture | PASS |
| Long-term follow-up boundary | PP Registry + approved architecture | PASS |
| Toxicity boundary | PP Registry + approved architecture | PASS |

---

# Layer 6 — Knowledge Graph QA

## Upstream / Prerequisite

| PP | Relationship | Result |
|---|---|---|
| PP-0196–0198 | Treatment/surgery context | PASS |
| PP-0203–0207 | Prior treatment context | PASS |
| PP-0213–0219 | Systemic therapy / assessment context | PASS |
| PP-0220 | Surveillance interface | PASS |
| PP-0221 | Recurrence-detection interface | PASS |
| PP-0228 | Supportive-care interface | PASS |

## Related

| PP | Relationship | Result |
|---|---|---|
| PP-0227 | Palliative-care context | PASS |
| PP-0231 | Treatment-toxicity interface | PASS |
| PP-0232 | Multidisciplinary coordination | PASS |

## Downstream

| PP | Relationship | Result |
|---|---|---|
| PP-0230 | Operational long-term follow-up | PASS |
| Dedicated nutrition packages | Detailed nutrition | PASS |
| Dedicated rehabilitation packages | Detailed rehabilitation | PASS |
| Dedicated psychosocial packages | Detailed psychosocial care | PASS |
| Dedicated prevention/screening packages | Detailed preventive algorithms | PASS |

---

# Layer 7 — Boundary QA

## Boundary 1 — PP-0220 Surveillance

**PASS**

PP-0229 references surveillance only as a component/interface of survivorship. Detailed surveillance schedules and modalities remain with PP-0220.

## Boundary 2 — PP-0221 Recurrence Detection

**PASS**

PP-0229 addresses fear/awareness of recurrence but does not build a recurrence-detection algorithm.

## Boundary 3 — PP-0228 Best Supportive Care

**PASS**

PP-0229 focuses on long-term survivor health and adaptation rather than the general active supportive-care framework.

## Boundary 4 — PP-0230 Long-term Follow-up

**PASS**

PP-0229 defines survivorship needs and care-plan content. PP-0230 retains operational longitudinal follow-up ownership.

## Boundary 5 — PP-0231 Treatment-related Toxicity and Supportive Care

**PASS**

PP-0229 includes persistent/late consequences at survivorship level but excludes detailed acute or therapy-specific toxicity management.

## Boundary 6 — Gastrectomy PPs

**PASS**

PP-0229 covers life after gastrectomy and long-term consequences but excludes surgical technique.

---

# Layer 8 — Clinical Safety QA

| Safety Item | Result | QA Note |
|---|---|---|
| No individualized treatment recommendation | PASS | No patient-specific therapy is prescribed. |
| No individualized surveillance schedule | PASS | Detailed surveillance delegated. |
| No individualized supplement dosing | PASS | Nutritional issues are described conceptually and conservatively. |
| No individualized exercise prescription | PASS | Physical activity is presented as a survivorship principle. |
| No individualized prognosis | PASS | Prognostic conclusions are excluded. |
| No recurrence diagnosis | PASS | Symptoms are not interpreted as recurrence. |
| No false cure claim | PASS | Survivorship is explicitly separated from cancer status. |
| No recurrence-prevention guarantee | PASS | Lifestyle advice is framed as health promotion. |
| Appropriate symptom escalation | PASS | New/worsening/persistent symptoms are directed to clinical assessment. |
| Specialist referral framing appropriate | PASS | Referral concepts are used without individualized prescriptions. |

---

# Layer 9 — Patient Misconception Review

The package explicitly addresses:

1. Treatment completion means all care ends.
2. Survivor means cured.
3. Survivorship equals surveillance.
4. Nutritional problems are always temporary.
5. Fatigue proves recurrence.
6. Neuropathy always resolves.
7. Healthy lifestyle guarantees no recurrence.
8. Oncology alone must provide all lifelong care.
9. Quality of life is secondary.
10. Follow-up ending means medical care ends.

**Result: PASS**

---

# Layer 10 — Evidence Gaps and Uncertainty

The following are intentionally preserved:

- survivorship care is individualized;
- exact follow-up schedules vary;
- nutritional monitoring varies by surgical context and patient factors;
- psychosocial needs vary;
- rehabilitation needs vary;
- screening depends on risk and applicable guidelines;
- evidence for some survivorship recommendations is consensus-heavy or based on smaller studies;
- detailed management belongs to dedicated packages.

**Result: PASS**

---

# Artifact Completeness Check

| Artifact | Present | Structural QA |
|---|---|---|
| 01_CKO.md | PASS | Metadata, objectives, scope, knowledge blocks, patient explanation, misconceptions, key messages, patient questions, graph, safety, boundary, revision history |
| 02_KNOWLEDGE_PASSPORT.md | PASS | Identity, classification, runtime relevance, scope, knowledge units, evidence classification, sources, graph, boundary, safety, governance and versioning |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | PASS | Clinical question, scope, primary/supporting sources, hierarchy, evidence matrix, evidence notes, use model, patient interpretation, gaps, delegation, traceability |
| 04_QA_REPORT.md | PASS | Content, clinical, educational, governance, traceability, graph, boundary, safety, misconception, evidence-gap and final quality review |

---

# Gold Depth Integrity

## Rule

Gold Reference Depth = Minimum Standard.

The package was not intentionally shortened, compacted, summarized, or reduced relative to the established Gold examples.

The artifacts preserve:

- substantive clinical reasoning;
- evidence traceability;
- Knowledge Graph depth;
- patient-facing explanatory depth;
- boundary reasoning;
- clinical safety;
- QA depth;
- governance metadata.

Complexity has been expanded where necessary because survivorship spans long-term treatment effects, nutrition, function, prevention, psychosocial care, and coordination.

**Result: PASS**

---

# Final Quality Decision

# PASS

PP-0229 satisfies the locked **FREEZE GOLD POPULATION PACKAGE SPECIFICATION** and the approved/locked PP-0229 Decision Batch.

The package preserves the intended architecture:

**Gastric Cancer Treatment**

↓

**Post-treatment transition**

↓

# PP-0229 — Gastric Cancer Survivorship

↓

**Long-term health / sequelae / prevention / quality of life / coordination**

with separate ownership for:

**PP-0220 — Surveillance**

**PP-0221 — Recurrence Detection**

**PP-0230 — Long-term Follow-up**

**PP-0231 — Treatment-related Toxicity and Supportive Care**

---

# Reviewer Notes

PP-0229 is an important bridge node in the gastric-cancer Knowledge Graph because it prevents the post-treatment branch from collapsing into a single “follow-up” concept.

Its distinctive ownership is:

> **Survivorship = the long-term health and lived-experience layer.**

The package deliberately preserves the distinction between:

- disease surveillance;
- recurrence detection;
- survivorship;
- operational follow-up;
- supportive care;
- treatment toxicity.

The most gastric-cancer-specific survivorship component is the long-term impact of gastrectomy, particularly nutritional and gastrointestinal consequences and their effects on function and quality of life.

---

# Final Status

**PASS — GOLD — READY FOR INTEGRATION.**
